Anthem Biosciences Ltd. (ANTHEM): Anthem Biosciences 52 Week High Streak: Second Straight Session Update
- September 3, 2026
- Posted by: Harsh Piplani
- Category: News
Anthem Biosciences 52 Week High Streak has extended to a second straight session, with the stock now at Rs 950.3 after a 2.94% cumulative move across the streak. The latest peak of Rs 954.6 matches the day high, and the latest Univest data confirms the price pattern but does not establish a company-specific catalyst for the continued move.
The share last traded above the previous close of Rs 933.85 after opening at Rs 947.55 and touching a low of Rs 932.9. Turnover stood at Rs 4.01 crore and market capitalisation at Rs 52,011.01 crore. For readers tracking Anthem Biosciences share price and stocks at one year high today, the repeated-high pattern matters because it shows a multi-session extension rather than a one-day breakout.
Anthem Biosciences Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 950.3 |
| Previous Close | Rs 933.85 |
| Today's Move | +Rs 16.45 (+1.76%) |
| Open | Rs 947.55 |
| High | Rs 954.6 |
| Low | Rs 932.9 |
| Turnover | Rs 4.01 crore |
| Market Capitalisation | Rs 52,011.01 crore |
Anthem Biosciences Ltd. (ANTHEM) traded at Rs 950.3 versus the previous close of Rs 933.85, a rise of 1.76%. The stock opened at Rs 947.55, reached a high of Rs 954.6 and touched a low of Rs 932.9.
Anthem Biosciences share price today reflects a firm start to the session, with the stock last traded at Rs 950.3, up Rs 16.45 or 1.76% from the previous close. The price opened near the upper half of the range at Rs 947.55, stayed above the earlier close, and moved to a high of Rs 954.6, which is also the fresh 52-week high for the streak. The low of Rs 932.9 kept the move contained within a relatively tight band around the prior close.
Turnover of Rs 4.01 crore provides a factual traded-value read for the session, while market capitalisation at Rs 52,011.01 crore places Anthem Biosciences among the larger listed names in the Healthcare space without implying anything about quality on its own. For investors following Anthem Biosciences stock news, the key point is that the move is not just a single-day spike: the stock has held the one-year peak for a second straight session, which makes the current share price update distinct from a one-off breakout story.
Anthem Biosciences Ltd. 52 Week High Streak: Consecutive High Analysis
Anthem Biosciences 52 Week High Streak now covers a second straight session, and the cumulative move across that stretch is 2.94%. The latest fresh one-year high is Rs 954.6, while the current price of Rs 950.3 remains close to that mark. This is the central differentiator from a single-day move: the stock has kept revisiting a higher 52-week peak on consecutive trading sessions.
The repeated-high pattern tells readers that the stock has remained at elevated price levels across more than one session, but it does not by itself explain why. The available numbers confirm the streak and the extent of the move; they do not provide a company-specific trigger. That is why the Anthem Biosciences new one year high again narrative should be read as a market-data pattern first, and only then alongside fundamentals and sector context.
What the Repeated 52-Week Highs Show
What the repeated 52-week highs show is simple: Anthem Biosciences is trading near the top of its one-year range for more than one session, and the latest print has stayed close to the fresh high. The gap between the previous close of Rs 933.85 and the latest price of Rs 950.3 shows that the stock has held above the prior reference level while making a new peak of Rs 954.6.
Anthem Biosciences Ltd. (ANTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 52,011.01 crore |
| P/E Ratio | 91.35x |
| P/B Ratio | 16.81x |
| ROE | 21.98% |
| ROCE | 29.62% |
| EPS | Rs 10.22 |
| Book Value Per Share | Rs 55.55 |
| Dividend Yield | 0.21% |
Anthem Biosciences Ltd. (ANTHEM) fundamental metrics show P/E 91.35x, P/B 16.81x, ROE 21.98%, ROCE 29.62%. These figures provide context only and are not a buy or sell signal.
Anthem Biosciences Ltd. has a market capitalisation of Rs 52011.01 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 91.35x, P/B at 16.81x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.98% and ROCE of 29.62%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 10.22, book value per share of Rs 55.55, dividend yield of 0.21%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.64x, median ROE of 11.78%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 91.35x |
| Benchmark Median P/E | 31.64x |
| Benchmark Average P/E | 48.34x |
| Benchmark P/E Range | 3.49x to 648.54x |
| Company P/B Ratio | 16.81x |
| Benchmark Median P/B | 2.83x |
| Company ROE | 21.98% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 29.62% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 52,011.01 crore |
| Benchmark Median Market Cap | Rs 692.19 crore |
Anthem Biosciences Ltd. (ANTHEM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Anthem Biosciences Ltd. (ANTHEM) has a P/E ratio of 91.35x, which is above the benchmark median of 31.64x, a difference of +188.72%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Anthem Biosciences Ltd. (ANTHEM) has a ROE of 21.98%, which is above the benchmark median of 11.78%, a difference of +86.59%. Anthem Biosciences Ltd. (ANTHEM) has a ROCE of 29.62%, which is above the benchmark median of 13.61%, a difference of +117.63%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | GLAXO | 50,732.03 | 46.73 | 19.81 | 48.76 | 66.79 |
| Ipca Laboratories Ltd. | IPCALAB | 50,384.39 | 37.89 | 5.85 | 15.88 | 19.41 |
| Abbott India Ltd. | ABBOTINDIA | 55,536.86 | 34.25 | 10.68 | 34.67 | 46.72 |
| Gland Pharma Ltd. | GLAND | 47,318.21 | 41.87 | 4.45 | 10.56 | 14.96 |
| Ajanta Pharma Ltd. | AJANTPHARM | 43,798.76 | 38.33 | 8.95 | 25.42 | 32.67 |
Anthem Biosciences Ltd. (ANTHEM) has a P/E ratio of 91.35x compared with the displayed peer median of 38.33x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 21.98% compares with a peer median of 25.42% across the companies shown in the table. ROCE stood at 29.62% versus the displayed peer median of 32.67%, providing a capital-efficiency comparison. Anthem Biosciences Ltd. (ANTHEM) has a market capitalisation of Rs 52,011.01 crore. Among the 5 peers shown, 1 has a larger market capitalisation.
Why Investors Are Watching Anthem Biosciences
- Anthem Biosciences 52 Week High Streak has now extended to a second straight session.
- The cumulative move across the streak stands at 2.94%.
- The stock touched a fresh 52-week high of Rs 954.6 in the latest trade.
- Turnover stood at Rs 4.01 crore and market capitalisation at Rs 52,011.01 crore.
- Valuation remains premium versus the sector median on both P/E and P/B.
About Anthem Biosciences Ltd.
Anthem Biosciences Ltd. is part of the Healthcare sector and the Pharmaceuticals & Drugs industry on the NSE and BSE. The company’s latest stock performance is being watched not only because of the repeated one-year high, but also because of its elevated market capitalisation, premium valuation and above-median return ratios within the industry benchmark. For readers tracking Anthem Biosciences company news, the focus remains on how the share price update aligns with business performance over coming periods.
The current reading also places Anthem Biosciences in the broader list of 52 Week High Stocks, where the repeated-high pattern can remain relevant as long as the stock keeps revisiting new one-year peaks across sessions.
Track Anthem Biosciences on Univest
Track Anthem Biosciences on Univest for the latest share price, stock news, company updates and market capitalisation snapshot. If you follow Anthem Biosciences stock performance, the stock page brings together the latest price, fundamentals and sector context in one place for quicker review.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Anthem Biosciences still hitting 52-week highs?
Ans. The latest price data confirms that Anthem Biosciences has set a fresh 52-week high for a second straight session. However, the numbers alone do not establish a company-specific catalyst for the repeated-high pattern.
How many sessions has Anthem Biosciences set a fresh one-year high?
Ans. Anthem Biosciences has now set a fresh 52-week high for its second straight session. The streak label matters because it shows the move has persisted across multiple trading sessions.
What is the cumulative gain across the Anthem Biosciences streak?
Ans. The cumulative move across the current Anthem Biosciences 52 Week High Streak is 2.94%. That figure covers the full repeated-high stretch rather than only the latest session.
What is the latest 52-week high for Anthem Biosciences?
Ans. The latest 52-week high for Anthem Biosciences is Rs 954.6. The stock last traded close to that level, which keeps the one-year peak central to the current share price update.
How does Anthem Biosciences compare with its previous close?
Ans. Anthem Biosciences last traded at Rs 950.3 versus the previous close of Rs 933.85. That reflects a rise of Rs 16.45, or 1.76%, from the prior reference level.
Is Anthem Biosciences expensive on valuation?
Ans. Anthem Biosciences trades at a P/E of 91.35 and a P/B of 16.81, both above the sector medians in the benchmark set. That points to a premium valuation relative to the group.
How do Anthem Biosciences fundamentals compare with peers?
Ans. Anthem Biosciences has ROE of 21.98% and ROCE of 29.62%, both above the industry medians shown in the benchmark set. Its valuation multiples are also higher than several peers, which is important for stock analysis.
What should investors track next in Anthem Biosciences?
Ans. Investors can monitor whether the stock continues to hold near its fresh high, how the valuation compares with future earnings delivery, and whether the repeated-high pattern extends beyond a second session. These are the main points for a market update.
Track Anthem Biosciences Ltd. (ANTHEM) Share Price on Univest
Use Anthem Biosciences Ltd. (ANTHEM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
